"Remission Induction" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapeutic act or process that initiates a response to a complete or partial remission level.
| Descriptor ID |
D012074
|
| MeSH Number(s) |
E02.860
|
| Concept/Terms |
Remission Induction- Remission Induction
- Induction, Remission
- Inductions, Remission
- Induction of Remission
- Remission Inductions
|
Below are MeSH descriptors whose meaning is more general than "Remission Induction".
Below are MeSH descriptors whose meaning is more specific than "Remission Induction".
This graph shows the total number of publications written about "Remission Induction" by people in this website by year, and whether "Remission Induction" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 17 | 17 |
| 1996 | 0 | 10 | 10 |
| 1997 | 0 | 11 | 11 |
| 1998 | 1 | 8 | 9 |
| 1999 | 0 | 7 | 7 |
| 2000 | 0 | 17 | 17 |
| 2001 | 0 | 8 | 8 |
| 2002 | 0 | 11 | 11 |
| 2003 | 0 | 14 | 14 |
| 2004 | 0 | 15 | 15 |
| 2005 | 1 | 13 | 14 |
| 2006 | 0 | 11 | 11 |
| 2007 | 1 | 16 | 17 |
| 2008 | 0 | 19 | 19 |
| 2009 | 0 | 16 | 16 |
| 2010 | 0 | 12 | 12 |
| 2011 | 1 | 21 | 22 |
| 2012 | 1 | 14 | 15 |
| 2013 | 0 | 15 | 15 |
| 2014 | 0 | 18 | 18 |
| 2015 | 0 | 16 | 16 |
| 2016 | 0 | 16 | 16 |
| 2017 | 0 | 13 | 13 |
| 2018 | 1 | 19 | 20 |
| 2019 | 2 | 17 | 19 |
| 2020 | 3 | 16 | 19 |
| 2021 | 0 | 13 | 13 |
| 2022 | 0 | 8 | 8 |
| 2023 | 0 | 18 | 18 |
| 2024 | 7 | 12 | 19 |
| 2025 | 1 | 9 | 10 |
To return to the timeline,
click here.
Below are the most recent publications written about "Remission Induction" by people in Profiles.
-
Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn's disease and ulcerative colitis. J Crohns Colitis. 2025 Jun 04; 19(6).
-
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia. Blood Adv. 2025 May 13; 9(9):2144-2152.
-
Corticosteroid Use in Randomized Clinical Trials of Biologics and Small Molecules in Inflammatory Bowel Disease: A Systematic Review. Inflamm Bowel Dis. 2025 May 12; 31(5):1430-1440.
-
Association of bile acid diarrhea with symptoms and disease activity in Crohn's disease: post-hoc clinical trial analysis of serum 7a-hydroxy-4cholestern-3-one, C4, in patients with active Crohn's disease. J Crohns Colitis. 2025 May 08; 19(5).
-
Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial. BMJ Open Gastroenterol. 2025 Mar 31; 12(1).
-
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia. 2025 May; 39(5):1058-1068.
-
Mirikizumab in the Treatment of Ulcerative Colitis: Initial Real-World Data in a Population from a Large Tertiary Center. Dig Dis Sci. 2025 May; 70(5):1864-1872.
-
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. J Crohns Colitis. 2025 Jan 11; 19(1).
-
Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial. Lancet Gastroenterol Hepatol. 2025 03; 10(3):210-221.
-
Real-World Effectiveness of Ustekinumab in Ulcerative Colitis in a United States Multicenter Cohort Consortium. Inflamm Bowel Dis. 2025 01 06; 31(1):131-139.